The plasma analysis suggested a significant (p < 0.05) elevation of hepatic injury biomarkers (AST and ALT) in response to CML, which was restored substantially using SO and OSO injection (Figure 6A). This evidence concerns the gene GPT and chronic myelogenous leukemia, BCR-ABL1 positive.